Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Greenhawt Matthew J. — Aquestive Therapeutics, Inc. insider: 2 transactions · InsiderLens

Home / Insiders / Greenhawt Matthew J.

Greenhawt Matthew J.

Chief Medical Officer at Aquestive Therapeutics, Inc. · on record since Mar 11, 2026

Insider trading activity of Greenhawt Matthew J.

Transactions on record: 2; since Mar 11, 2026

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Mar 11, 2026

Figures computed from official regulatory filings — methodology.

Companies where Greenhawt Matthew J. has traded

Aquestive Therapeutics, Inc.2 tx · $214.5K · Mar 11, 2026

Track record of Greenhawt Matthew J.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Greenhawt Matthew J.

Co-insiders of Greenhawt Matthew J.

Barber DanielAquestive Therapeutics, Inc.
Boyd Peter E.Aquestive Therapeutics, Inc.
BRAENDER LORI JAquestive Therapeutics, Inc.
Bratton Capital Inc.Aquestive Therapeutics, Inc.
Bratton Capital Management, L.P.Aquestive Therapeutics, Inc.
BRATTON DOUGLAS KAquestive Therapeutics, Inc.
BROWN GREGORY BAquestive Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Cioffi MelinaAquestive Therapeutics, Inc.

Cochran JohnAquestive Therapeutics, Inc.

COSTA SANTO JAquestive Therapeutics, Inc.

Davis Matthew W.Aquestive Therapeutics, Inc.

Jenkins Abigail L.Aquestive Therapeutics, Inc.

Jung CassieAquestive Therapeutics, Inc.

Kendall Keith JAquestive Therapeutics, Inc.

Korczynski SherryAquestive Therapeutics, Inc.

Kraus Carl NAquestive Therapeutics, Inc.

Krop JulieAquestive Therapeutics, Inc.

Lurker NancyAquestive Therapeutics, Inc.

Marshall Ken W.Aquestive Therapeutics, Inc.

Maxwell John T.Aquestive Therapeutics, Inc.

Monoline Partners, L.P.Aquestive Therapeutics, Inc.

Monoline RX III, L.P.Aquestive Therapeutics, Inc.

MonoLine RX II, L.P.Aquestive Therapeutics, Inc.

MonoLine RX, L.P.Aquestive Therapeutics, Inc.

MonoSol Rx Genpar, L.P.Aquestive Therapeutics, Inc.

MORRIS TIMOTHY EAquestive Therapeutics, Inc.

MRX Partners, LLCAquestive Therapeutics, Inc.

Schobel Alexander MarkAquestive Therapeutics, Inc.

Scibetta James SAquestive Therapeutics, Inc.

Slatko Gary HAquestive Therapeutics, Inc.

Taglietti MarcoAquestive Therapeutics, Inc.

TOTH A ERNEST JRAquestive Therapeutics, Inc.

Truitt KennethAquestive Therapeutics, Inc.

Wargacki StephenAquestive Therapeutics, Inc.

Wood TheresaAquestive Therapeutics, Inc.

Zalewski Thomas A.Aquestive Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Aquestive Therapeutics, Inc.	Mar 11, 2026	AwardD	50,000	4.29 USD	$214.5K	SEC
Aquestive Therapeutics, Inc.	Mar 11, 2026	Award	75,000	0.00 USD	$0	SEC